Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03854305 | Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease | PHASE2 | COMPLETED | 93 | — | — | Mar 1, 2018 | Aug 1, 2019 | Sep 15, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| PRV-6527 | DRUG | Treatment |
| Placebo | DRUG | Comparator |